ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2027

Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus

Kelly Wise1, Fatima Barbar-Smiley2, Stephanie Lemle2, Darby MacDonald2, Ohoud AlAhmed3, Evan Mulvihill4, William Cotton2, Monica Ardura2, Cagri Yildirim-Toruner5 and Vidya Sivaraman6,7, 1Pharmacy/Rheumatology, Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Pediatrics, Nationwide Children's Hospital, Columbus, OH, 4Pediatrics and Rheumatology, Nationwide Children's Hospital and The Ohio State University, Columbus, OH, 5Rheumatology, Nationwide Children's Hospital, Columbus, OH, 6Pediatric Rheumatology, Nationwide Children's Hospital, Columbus, OH, 7Pediatrics, The Ohio State University, COLUMBUS, OH

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: juvenile SLE, Quality improvement and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Measures and Measurement of Healthcare Quality Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Patients with Systemic Lupus Erythematosus (SLE) lupus are up to 13 times more likely to develop invasive pneumococcal infections, resulting in increased morbidity and mortality. Vaccination against S. pneumoniae is therefore recommended in all patients with SLE, however, vaccination rates in routine rheumatology care remain low. Barriers to vaccination are lack of provider recommendation, concerns about vaccine efficacy and safety, lack of vaccine supply, incomplete immunization records and time. The aim of this study was to increase pneumococcal vaccination rates in patients with Childhood-onset SLE (c-SLE) from 3.6% to 50% in 1 year and 80% by the following year. This report describes the interim results at 9-months from the initiation of the project.

Methods:

Patients with childhood-onset SLE followed in the pediatric rheumatology clinic at Nationwide Children’s Hospital from 1/1/2015 to 8/31/2016 were included for the baseline analysis. Newly diagnosed patients with c-SLE were included for the ongoing study. A letter was sent to these patients and their primary care providers requesting an updated immunization record. An age-based algorithm was developed for pneumococcal conjugate (PCV13) and pneumococcal polysaccharide (PPSV23) vaccination based on current ACIP guidelines, followed by an education session for rheumatology providers and clinic staff. Pre-visit planning included: 1) Generating a weekly report of upcoming appointments for c-SLE patients, 2) Entering updated immunization records with the help of the clinical pharmacist in the electronic health record (EHR), identifying candidates for vaccination, and notifying the rheumatology team of vaccination opportunities on a weekly basis, and 3) Weekly monitoring by clinic nurses to ensure adequate vaccine stock.

Results:

83 patients with c-SLE were seen in the pediatric rheumatology clinic in the baseline period, with a median age of 18.3 years (range 7-24). An additional 8 newly diagnosed patients were included in this analysis, with a total of 91 patients. Over the study period, the number of patients with updated vaccine records in the EHR increased from 25.6% to 65.1%. Vaccination rates for PCV13 increased from 8.4% to 49.4% (p<0.0001) and PPSV-23 rates increased from 24.1% to 32.9%. A total of 20/91 (21.9%) were appropriately immunized with both vaccines, compared with 3.6% at baseline (p<0.0001). Notably, 60.4% of patients had received at least 1 dose of pneumococcal vaccine as compared to 28.9% at the start of the study (p<0.0001).

Conclusion:

This study highlights the benefits of pre-visit planning in improving pneumococcal vaccination in patients with c-SLE. Access to updated immunization records in the EHR at the time of the visit facilitated timely decision making. Targeted vaccine recommendations prior to the visit minimized the time burden on providers and served as a reminder to order the vaccine. Future efforts will be directed at building clinical decision support in the EHR for vaccinations in high-risk individuals, evaluating vaccine immunogenicity and expanding the service to patients with other pediatric rheumatic diseases.


Disclosure: K. Wise, None; F. Barbar-Smiley, None; S. Lemle, None; D. MacDonald, None; O. AlAhmed, None; E. Mulvihill, None; W. Cotton, None; M. Ardura, None; C. Yildirim-Toruner, None; V. Sivaraman, None.

To cite this abstract in AMA style:

Wise K, Barbar-Smiley F, Lemle S, MacDonald D, AlAhmed O, Mulvihill E, Cotton W, Ardura M, Yildirim-Toruner C, Sivaraman V. Pre-Visit Planning Improves Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/pre-visit-planning-improves-pneumococcal-vaccination-in-patients-with-childhood-onset-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/pre-visit-planning-improves-pneumococcal-vaccination-in-patients-with-childhood-onset-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology